These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 3903562)

  • 21. 3-Hydroxy-3-methylglutaryl--coenzyme A reductase inhibitors in the treatment of hypercholesterolemia.
    Hoeg JM; Brewer HB
    JAMA; 1987 Dec; 258(24):3532-6. PubMed ID: 3316727
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dihydromevinolin, a potent hypocholesterolemic metabolite produced by Aspergillus terreus.
    Albers-Schönberg G; Joshua H; Lopez MB; Hensens OD; Springer JP; Chen J; Ostrove S; Hoffman CH; Alberts AW; Patchett AA
    J Antibiot (Tokyo); 1981 May; 34(5):507-12. PubMed ID: 7275832
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Drugs inhibiting HMG-CoA reductase.
    Endo A
    Pharmacol Ther; 1985; 31(3):257-67. PubMed ID: 3843353
    [No Abstract]   [Full Text] [Related]  

  • 24. RG 12561 (dalvastatin): a novel synthetic inhibitor of HMG-CoA reductase and cholesterol-lowering agent.
    Amin D; Gustafson SK; Weinacht JM; Cornell SA; Neuenschwander K; Kosmider B; Scotese AC; Regan JR; Perrone MH
    Pharmacology; 1993; 46(1):13-22. PubMed ID: 8434028
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Influence of mevinolin on experimental atherosclerosis in rabbits.
    Kritchevsky D; Tepper SA; Klurfeld DM
    Pharmacol Res Commun; 1981 Nov; 13(10):921-6. PubMed ID: 6918018
    [No Abstract]   [Full Text] [Related]  

  • 26. Sterol biosynthesis: effect of compactin and its derivatives.
    Fears R
    Biochem Soc Trans; 1983 Dec; 11(6):642-4. PubMed ID: 6559718
    [No Abstract]   [Full Text] [Related]  

  • 27. Inhibitors of cholesterol biosynthesis increase hepatic low-density lipoprotein receptor protein degradation.
    Ness GC; Zhao Z; Lopez D
    Arch Biochem Biophys; 1996 Jan; 325(2):242-8. PubMed ID: 8561503
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Relationship between mevalonate and mitogenesis in human fibroblasts stimulated with platelet-derived growth factor.
    Fairbanks KP; Witte LD; Goodman DS
    J Biol Chem; 1984 Feb; 259(3):1546-51. PubMed ID: 6693424
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The effect of mevinolin on steroidogenesis in patients with defects in the low density lipoprotein receptor pathway.
    Laue L; Hoeg JM; Barnes K; Loriaux DL; Chrousos GP
    J Clin Endocrinol Metab; 1987 Mar; 64(3):531-5. PubMed ID: 3029155
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Monacolin M, a new inhibitor of cholesterol biosynthesis.
    Endo A; Komagata D; Shimada H
    J Antibiot (Tokyo); 1986 Dec; 39(12):1670-3. PubMed ID: 3818440
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Residual effects of lovastatin and simvastatin on urinary mevalonate excretions in patients with familial hypercholesterolemia.
    Pappu AS; Bacon SP; Illingworth DR
    J Lab Clin Med; 2003 Apr; 141(4):250-6. PubMed ID: 12677170
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The effects of mevinolin on serum cholesterol levels of rabbits with endogenous hypercholesterolemia.
    Kroon PA; Hand KM; Huff JW; Alberts AW
    Atherosclerosis; 1982 Jul; 44(1):41-8. PubMed ID: 6921995
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Red yeast rice can lower cholesterol but should not replace established therapy].
    Gustafsson LL
    Lakartidningen; 2011 Dec 14-20; 108(50):2662. PubMed ID: 22474784
    [No Abstract]   [Full Text] [Related]  

  • 34. Plasma cholesterol is hyperresponsive to statin in ABCG5/ABCG8 transgenic mice.
    Tang W; Ma Y; Yu L
    Hepatology; 2006 Nov; 44(5):1259-66. PubMed ID: 17058264
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Monacolin K, a new hypocholesterolemic agent that specifically inhibits 3-hydroxy-3-methylglutaryl coenzyme A reductase.
    Endo A
    J Antibiot (Tokyo); 1980 Mar; 33(3):334-6. PubMed ID: 7380744
    [No Abstract]   [Full Text] [Related]  

  • 36. Cholesterol synthesis inhibitors do not reduce Lp(a) levels in normocholesterolemic patients.
    Pazzucconi F; Franceschini G; Gianfranceschi G; Campagnoli G; Sirtori CR
    Pharmacol Res; 1996; 34(3-4):131-3. PubMed ID: 9051704
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Normal cholesterol levels with lovastatin (mevinolin) therapy in a child with homozygous familial hypercholesterolemia following liver transplantation.
    East C; Grundy SM; Bilheimer DW
    JAMA; 1986 Nov; 256(20):2843-8. PubMed ID: 3534334
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Current and future pharmacologic options for the management of patients unable to achieve low-density lipoprotein-cholesterol goals with statins.
    El Harchaoui K; Akdim F; Stroes ES; Trip MD; Kastelein JJ
    Am J Cardiovasc Drugs; 2008; 8(4):233-42. PubMed ID: 18690757
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hypocholesterolemic effect of lycopene and beta-carotene is related to suppression of cholesterol synthesis and augmentation of LDL receptor activity in macrophages.
    Fuhrman B; Elis A; Aviram M
    Biochem Biophys Res Commun; 1997 Apr; 233(3):658-62. PubMed ID: 9168909
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Inhibitors of cholesterol synthesis: a welcome addition].
    van 't Laar A
    Ned Tijdschr Geneeskd; 1989 Feb; 133(7):332-4. PubMed ID: 2927552
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.